359 related articles for article (PubMed ID: 22138097)
21. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.
Hall PS; Hulme C; McCabe C; Oluboyede Y; Round J; Cameron DA
Pharmacoeconomics; 2011 May; 29(5):415-32. PubMed ID: 21504241
[TBL] [Abstract][Full Text] [Related]
22. [Cost-Effectiveness of the 21 Gene Assay in Patients with Node-Positive Breast Cancer].
Fischer L; Arnold M; Kirsch F; Leidl R
Gesundheitswesen; 2016 Nov; 78(11):772-780. PubMed ID: 26107965
[No Abstract] [Full Text] [Related]
23. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
24. [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region].
Nerich V; Curtit E; Bazan F; Montcuquet P; Villanueva C; Chaigneau L; Cals L; Méneveau N; Dobi E; Altmotlak H; Algros MP; Choulot MJ; Nallet G; Limat S; Mansion S; Pivot X
Bull Cancer; 2014; 101(7-8):681-9. PubMed ID: 25091650
[TBL] [Abstract][Full Text] [Related]
25. Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial.
Hall PS; Smith A; Hulme C; Vargas-Palacios A; Makris A; Hughes-Davies L; Dunn JA; Bartlett JMS; Cameron DA; Marshall A; Campbell A; Macpherson IR; Dan Rea ; Francis A; Earl H; Morgan A; Stein RC; McCabe C;
Value Health; 2017 Dec; 20(10):1311-1318. PubMed ID: 29241890
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
Schwartz NRM; Flanagan MR; Babigumira JB; Steuten LM; Roth JA
J Manag Care Spec Pharm; 2019 Oct; 25(10):1133-1139. PubMed ID: 31556818
[TBL] [Abstract][Full Text] [Related]
27. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective.
Berdunov V; Laws E; Cuyun Carter G; Luo R; Russell C; Campbell S; Force J; Abdou Y
J Med Econ; 2023; 26(1):973-990. PubMed ID: 37466220
[TBL] [Abstract][Full Text] [Related]
28. Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective.
Kip M; Monteban H; Steuten L
J Comp Eff Res; 2015 Sep; 4(5):433-45. PubMed ID: 25872415
[TBL] [Abstract][Full Text] [Related]
29. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
30. A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer.
Huxley N; Jones-Hughes T; Coelho H; Snowsill T; Cooper C; Meng Y; Hyde C; Mújica-Mota R
Health Technol Assess; 2015 Jan; 19(2):v-xxv, 1-215. PubMed ID: 25586547
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.
Hannouf MB; Xie B; Brackstone M; Zaric GS
BMC Cancer; 2012 Oct; 12():447. PubMed ID: 23031196
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
[TBL] [Abstract][Full Text] [Related]
33. Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
Katz G; Romano O; Foa C; Vataire AL; Chantelard JV; Hervé R; Barletta H; Durieux A; Martin JP; Salmon R
PLoS One; 2015; 10(6):e0128880. PubMed ID: 26086912
[TBL] [Abstract][Full Text] [Related]
34. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).
Kondo M; Hoshi SL; Yamanaka T; Ishiguro H; Toi M
Breast Cancer Res Treat; 2011 Jun; 127(3):739-49. PubMed ID: 21082239
[TBL] [Abstract][Full Text] [Related]
35. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
37. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
38. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
39. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
Messori A; Becagli P; Trippoli S; Tendi E
Eur J Clin Pharmacol; 1996; 51(2):111-6. PubMed ID: 8911873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]